{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:28:52Z","timestamp":1780507732688,"version":"3.54.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>This study aimed to gain deeper insights into the hepatotoxicity mechanisms of valproic acid (VPA), as well as to identify potential risk markers for VPA-induced hepatotoxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty-two children with epilepsy treated with VPA monotherapy were divided into a normal liver function (NLF) group, a mild abnormal liver function (ANLF1) group, and a serious abnormal liver function (ANLF2) group based on their liver function indicator levels. The full quantitative targeted metabolomics technique was used to systematically investigate how the differential endogenous metabolic components change with the development of liver injury.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 195 metabolic components were quantitatively analyzed. Nineteen identified metabolites, including five organic acids, four short-chain fatty acids, four amino acids, three fatty acids, and three benzenoids, differed significantly among the three groups, showing a strong association with VPA-induced hepatotoxicity. Only three bile acid metabolites, taurodeoxycholic acid, taurochenodeoxycholic acid, and deoxycholic acid, were significantly different between the ANLF1 and ANLF2 groups, increasing at first and then decreasing with the aggravation of liver injury. The mechanistic evaluation showed that SRT1720 activation could alleviate the severity of liver function abnormalities induced by VPA. Immunocoprecipitation indicated that VPA significantly increased the acetylation level of FXR, and the application of agonist SRT1720 can antagonize the acetylation of FXR by VPA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Nineteen identified metabolites showed a strong association with hepatotoxicity and three bile acid metabolites changed with the development of liver injury. The SIRT1\u2013FXR pathway was firstly proposed to participate in VPA-induced hepatotoxicity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1477619","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T04:44:14Z","timestamp":1730954654000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["The role of SIRT1-FXR signaling pathway in valproic acid induced liver injury: a quantitative targeted metabolomic evaluation in epileptic children"],"prefix":"10.3389","volume":"15","author":[{"given":"Mingming","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cbi.2017.12.003","article-title":"Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells","volume":"280","author":"Aztopal","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.taap.2017.03.022","article-title":"Valproate induced hepatic steatosis by enhanced fatty acid uptake and triglyceride synthesis","volume":"324","author":"Bai","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"13850","DOI":"10.1074\/jbc.M112.443937","article-title":"SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes","volume":"288","author":"Balasubramaniyan","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"100342","DOI":"10.1016\/j.ebr.2019.100342","article-title":"Acute liver failure in a military recruit treated with valproic acid and harboring a previously unrecognized POLG-1 mutation","volume":"12","author":"Bassett","year":"2019","journal-title":"Epilepsy Behav. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"vdz025","DOI":"10.1093\/noajnl\/vdz025","article-title":"Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples","volume":"1","author":"Berendsen","year":"2019","journal-title":"Neurooncol Adv."},{"key":"B6","doi-asserted-by":"publisher","first-page":"108238","DOI":"10.1016\/j.pharmthera.2022.108238","article-title":"Bile acid metabolism and signaling, the microbiota, and metabolic disease","volume":"237","author":"Cai","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.bbadis.2017.09.019","article-title":"Nuclear receptor FXR, bile acids and liver damage: introducing the progressive familial intrahepatic cholestasis with FXR mutations","volume":"1864","author":"Cariello","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/03602530600959433","article-title":"Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity","volume":"38","author":"Chang","year":"2006","journal-title":"Drug Metab. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"113669","DOI":"10.1016\/j.bcp.2019.113669","article-title":"Association between the perturbation of bile acid homeostasis and valproic acid-induced hepatotoxicity","volume":"170","author":"Chen","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF03259935","article-title":"Valproate-associated hepatotoxicity and its biochemical mechanisms","volume":"3","author":"Eadie","year":"1988","journal-title":"Med. Toxicol. Adverse Drug Exp."},{"key":"B11","doi-asserted-by":"publisher","first-page":"35086","DOI":"10.1074\/jbc.M803531200","article-title":"The p300 acetylase is critical for ligand-activated farnesoid X receptor (FXR) induction of SHP","volume":"283","author":"Fang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.apsb.2015.01.001","article-title":"Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids","volume":"5","author":"Ferrebee","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"B13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1124\/mol.119.118646","article-title":"Obeticholic acid ameliorates valproic acid-induced hepatic steatosis and oxidative stress","volume":"97","author":"Gai","year":"2020","journal-title":"Mol. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/20009666.2018.1514933","article-title":"Valproic acid induced acute liver injury resulting in hepatic encephalopathy-a case report and literature review","volume":"8","author":"Gayam","year":"2018","journal-title":"J. Community Hosp. Intern Med. Perspect."},{"key":"B15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.seizure.2007.04.003","article-title":"Reversible hepatotoxicity, pancreatitis, coagulation disorder and simultaneous bone marrow suppression with valproate in a 2-year-old girl","volume":"16","author":"Gerstner","year":"2007","journal-title":"Seizure"},{"key":"B16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2174\/1381612825666190329145428","article-title":"Valproic acid and the liver injury in patients with epilepsy: an update","volume":"25","author":"Guo","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"B18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1080\/07853890902729794","article-title":"Metabolomics: unraveling the chemical individuality of common human diseases","volume":"41","author":"Houten","year":"2009","journal-title":"Ann. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jchromb.2014.08.011","article-title":"An effective assessment of valproate sodium-induced hepatotoxicity with UPLC-MS and (1)HNMR-based metabonomics approach","volume":"969","author":"Huo","year":"2014","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.phymed.2015.06.007","article-title":"Activation of the farnesoid X receptor attenuates triptolide-induced liver toxicity","volume":"22","author":"Jin","year":"2015","journal-title":"Phytomedicine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cmet.2009.09.009","article-title":"FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states","volume":"10","author":"Kemper","year":"2009","journal-title":"Cell metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1177\/1091581809340329","article-title":"Metabolomics study with gas chromatography-mass spectrometry for predicting valproic acid-induced hepatotoxicity and discovery of novel biomarkers in rat urine","volume":"28","author":"Lee","year":"2009","journal-title":"Int. J. Toxicol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/15563650902752376","article-title":"Carnitine in the treatment of valproic acid-induced toxicity","volume":"47","author":"Lheureux","year":"2009","journal-title":"Clin. Toxicol. (Phila)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2017.01.030","article-title":"Valproate acid (VPA)-induced dysmetabolic function in clinical and animal studies","volume":"468","author":"Li","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"B25","doi-asserted-by":"publisher","first-page":"116509","DOI":"10.1016\/j.taap.2023.116509","article-title":"Suppression of SIRT1\/FXR signaling pathway contributes to oleanolic acid-induced liver injury","volume":"467","author":"Liao","year":"2023","journal-title":"Toxicol Appl Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin. Biochem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrd728","article-title":"Metabonomics: a platform for studying drug toxicity and gene function","volume":"1","author":"Nicholson","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"B28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/gut.25.6.673","article-title":"Hepatotoxicity to sodium valproate: a review","volume":"25","author":"Powell-Jackson","year":"1984","journal-title":"Gut"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1128\/MCB.05988-11","article-title":"Hepatic deletion of SIRT1 decreases hepatocyte nuclear factor 1\u03b1\/farnesoid X receptor signaling and induces formation of cholesterol gallstones in mice","volume":"32","author":"Purushotham","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bbalip.2014.04.008","article-title":"Bile acid signaling in lipid metabolism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice","volume":"1851","author":"Qi","year":"2015","journal-title":"Biochimica biophysica acta"},{"key":"B32","first-page":"454","article-title":"Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid","volume":"14","author":"Rettenmeier","year":"1986","journal-title":"Drug Metab. Dispos."},{"key":"B33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-0032-1323671","article-title":"Non-fatal and fatal liver failure associated with valproic acid","volume":"46","author":"Schmid","year":"2013","journal-title":"Pharmacopsychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e108970","DOI":"10.1371\/journal.pone.0108970","article-title":"Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase","volume":"9","author":"Star","year":"2014","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1021\/tx950120y","article-title":"Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC\/MS\/MS characterization of the GSH-glucuronide diconjugates","volume":"9","author":"Tang","year":"1996","journal-title":"Chem. Res. Toxicol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrd.2016.32","article-title":"Emerging applications of metabolomics in drug discovery and precision medicine","volume":"15","author":"Wishart","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"B39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.taap.2013.01.018","article-title":"Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats","volume":"268","author":"Yamazaki","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"B40","first-page":"99","article-title":"Metabonomics for discovering biomarkers of hepatotoxicity and nephrotoxicity","volume":"67","author":"Zhang","year":"2012","journal-title":"Pharmazie"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1477619\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T04:44:18Z","timestamp":1730954658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1477619\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":40,"alternative-id":["10.3389\/fphar.2024.1477619"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1477619","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"article-number":"1477619"}}